Daraxonrasib shows promising results for patients grappling with advanced pancreatic cancer. This innovative oral medication carefully targets a specific gene mutation that propels cancer’s progression. Clinical trials reveal a substantial increase in both overall and progression-free survival rates. As physicians regard it as a potential new benchmark for second-line treatment, expanded access continues while additional studies are conducted.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.